[Pathophysiology of antibody-associated diseases of the central nervous system].
Antibodies against intracellular antigens have been known since the 1980s and 1990s but in recent years antibodies against surface antigens have also been discovered. These are "more interesting" than those to intracellular targets in two respects: they result in a better response to immunotherapy and are probably directly pathogenic, which helps to understand the disease mechanisms. There are the destructive and irreversible effects of the antibodies to antigens that are complexed with voltage-gated potassium channels (VGKC complex antibodies), especially antibodies to leucine-rich glioma inactivated 1 (LGI1) on the one hand. On the other hand, antibodies may have reversible functional effects, such as antibodies against the N-methyl-D-aspartate receptor, which cause an internalization of these receptors but do not lead to cell destruction: LGI1 antibodies also seem to have functional, in this case epileptogenic effects. These emerging findings make plausible why antibody-reducing therapies provide opportunities for the restoration of health in affected patients.